Related Stories
CDC's Covid-19 Vaccine v-safe Data Released Pursuant to Court Order
Key Excerpts from Article on Website of PR Newswire
Posted: October 24th, 2022
https://www.prnewswire.com/news-releases/cdcs-covid-19-vacci...
In response to a lawsuit filed by Siri & Glimstad LLP on behalf of the Informed Consent Action Network (ICAN), the CDC has released the first set of data from its v-safe program. V-safe is a smartphone-based program created by CDC specifically for Covid-9 vaccines. It allows users to register and provide health check-ins after receiving a Covid-19 vaccine. Out of the approximate 10 million v-safe users, 782,913 individuals, or over 7.7% of v-safe users, had a health event requiring medical attention, emergency room intervention, and/or hospitalization. Another 25% of v-safe users had an event that required them to miss school or work and/or prevented normal activities. There were also 71 million symptoms reported in the pre-populated fields. This is an average of more than 7 symptoms reported per v-safe user. Reported symptoms include, for example, over 4 million reports of joint pain. While around 2 million of these joint pain reports were mild, over 1.8 million were for moderate joint pain and over 400,000 were for severe joint pain. There were also around 13,000 infants under 2 years of age registered in v-safe. Among these infants, over 33,000 symptoms were reported, with the most common symptoms being irritability, sleeplessness, pain, and loss of appetite. The data also reflects a disproportionate amount of negative health impacts, including medical events, following the Moderna vaccine versus the Pfizer vaccine and shows a disproportionate number of negative events reported by women versus men.
Note: For lots more on this important development with access to the data, see this webpage. For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
Related Stories
Latest News
Key News Articles from Years Past
